Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.